SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. __)*

BIOVENTUS INC.

(Name of Issuer)

Class A Common Stock, par value $0.001 per share

(Title of Class of Securities)

09075A108

(CUSIP Number)

Martin P. Sutter

EW Healthcare Partners Acquisition Fund, L.P.

21 Waterway Avenue, Suite 225

The Woodlands, Texas 77380

(281) 364-1555

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

December 31, 2021

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13G

ORIGINAL REPORT ON SCHEDULE 13G

Item 1.

(a) Name of Issuer: BIOVENTUS INC.

(b) Address of Issuer’s Principal Executive Offices:

4721 Emperor Boulevard, Suite 100

Durham, North Carolina 27703

Item 2.

(a) Name of Person Filing: This Schedule 13G is being filed jointly by EW Healthcare Partners Acquisition Fund, L.P., a Delaware limited partnership (“EWHP”), White Pine Medical LLC, a Delaware limited liability company (“WPM”), EW Healthcare Partners Acquisition Fund GP, L.P., a Delaware limited partnership, the general partner of EWHP (the “EWHP GP”), EW Healthcare Partners Acquisition Fund UGP, LLC, a Delaware limited liability company, the general partner of EWHP GP (the “General Partner”), Martin P. Sutter, an individual, Petri Vainio, an individual, Ron Eastman, an individual, and R. Scott Barry, an individual, (each a “Manager”, collectively, the “Managers”, and together with EWHP, WPM, EWHP GP and the General Partner, the “Reporting Persons”).

(b) Address of Principal Business Office: The address of the principal business of each of the Reporting Persons is 21 Waterway, Suite 225, The Woodlands, Texas 77380.

(c) Citizenship: (i) EWHP and EWHP GP are each Delaware limited partnerships; (ii) WPM and the General Partner are each a Delaware limited liability company; and (iii) each of Martin P. Sutter, Petri Vainio, Ron Eastman and R. Scott Barry are all individuals who are citizens of the United States.

(d) Title and Class of Securities: Class A Common Stock, par value $.001 per share

(e) CUSIP Number: 09075A108

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

For EWHP, 12,096,702 shares.

For WPM, 924,622 shares

For each of EWHP GP and the General Partner, 13,021,324 shares.

For each of the Managers: 13,021,324 shares.

For EWHP, 16.1%.

For WPM, 1.2%

For each of EWHP GP and the General Partner, 17.31 %.

For each of the Managers: 17.31%.

(i) Sole power to vote or to direct the vote:

For EWHP, 12,096,702 shares.

For WPM, 924,622 shares.

For each of EWHP GP and the General Partner, 13,021,324 shares.

For each of the Managers: 0 shares.

(ii) Shared power to vote or to direct the vote:

For EWHP, 0 shares.

For WPM, 0 shares.

For each of EWHP GP and the General Partner, 0 shares.

For each of the Managers: 13,021,324 shares.

(iii) Sole power to dispose or to direct the disposition of:

For EWHP, 12,096,702 shares.

For WPM, 924,622 shares.

For each of EWHP GP and the General Partner, 13,021,324 shares.

For each of the Managers: 0 shares.

(iv) Shared power to dispose or to direct the disposition of:

For EWHP, 0 shares.

For WPM, 0 shares.

For each of EWHP GP and the General Partner, 0 shares.

For each of the Managers: 13,021,324 shares.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

Item 6. Ownership of More than Five Percent on Behalf of Another Person

N/A

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company

N/A

Item 8. Identification and Classification of Members of the Group

N/A

Item 9. Notice of Dissolution of Group

N/A

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having the purpose or effect.

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Date: January 31, 2022

Exhibit 1

JOINT FILING AGREEMENT

Each of the undersigned agrees that (i) the statement on Schedule 13G relating to the Class A Common Stock of Bioventus, Inc., has been adopted and filed on behalf of each of them, (ii) all future amendments to such statement on Schedule 13G/A will, unless written notice to the contrary is delivered as described below, be jointly filed on behalf of each of them, and (iii) the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934 apply to each of them. This agreement may be terminated with respect to the obligations to jointly file future amendments to such statement on Schedule 13G/A as to any of the undersigned upon such person giving written notice thereof to each of the other persons signature hereto, at the principal office thereof.

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Date: January 31, 2022